Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why

Shares of Puma Biotechnology, Inc. (PBYI) have rallied 24% in the past three months against the industry’s decline of 9.7%.The company’s sole marketed product, Nerlynx (neratinib), is approved for treating early-stage HER2-positive breast cancer in patients previously treated with Roche’s (RHHBY) Herceptin-based adjuvant therapy.In the first nine months of 2024, Nerlynx generated sales worth $140.8 million. Sales of the drug improved in the third quarter of 2024 and came ahead of management’s expectations.O ...